Business
Spectral Medical Announces Fourth Quarter and Fiscal 2024 Results and Provides Corporate Update
TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or ...
About this update from Spectral Medical Inc
[{"type":"text","content":"Spectral Medical Announces Fourth Quarter and Fiscal 2024 Results and Provides Corporate Update154 patients enrolled\n\n\n\n TORONTO, March 27, 2025 (GLOBE NEWSWIRE) --\n \n Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),\n \n a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2024 and provided a corporate update.\n \n\n The Company made significant progress throughout 2024, both clinically and operationally. Specifically, regarding its Tigris trial, a Phase III clinical trial evaluating PMX for endotoxic septic shock. The Company has successfully enrolled 154 patients to date and is focused on the final push to fully enroll and finish the Tigris trial. The Company believes that the continued onboarding of new Tigris sites since the fourth quarter of 2023 could further accelerate enrollment experienced to date and allow Spectral to rapidly reach the 150 evaluable patient target, bringing the Company closer to FDA submission and potential FDA approval. In parallel to its clinical trial, the Company continues to work closely with its commercialization partner, Vantive US Healthcare LLC (“Vantive”); and most recently the parties collaborated on completing the PrisMax sub-study in February 2025.\n \n\n Dr. John Kellum, Chief Medical Officer of Spectral Medical, stated, “We are very much in the final stretch of enrollment into Tigris, and we look forward to finalizing enrollment in the next few weeks. We are committed to advancing Tigris and believe PMX, if ultimately approved, will play a major role in reducing the tragic rates of mortality caused by sepsis.”\n \n\n\n\n Corporate Highlights During & Subsequent to the Fourth Quarter and Fiscal Year Ended December 31, 2024\n \n\n\n\n\n Tigris:\n \n\n\n\n Total of 154 patients randomized to date in the Tigris trial.\n \n\n Despite enrollment headwinds experienced in the fourth quarter of 2024, due to the impact of Hurricane Helene on the medical supply chain, Tigris 2024 enrollment was incredibly robust\n \n\n 59 patients enrolled in 2024 vs. 31 patients enrolled in 2023\n \n\n\n\n Strong start to 2025 enrollment\n \n\n 14 patients enrolled 2025 year-to-date\n \n\n\n\n\n\n Ti...